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Abstract 
Lung cancer, the most prevalent and deadly malignancy in the world, poses a particularly critical healthcare challenge 
to China due to the rapidly increasing new cases and the unique cancer genetics in Chinese patient population. Sub-
stantial progress has been made in molecular diagnosis and personalized treatment of the disease. The field is now 
moving towards multiple new directions to include (1) new generation of targeted agents such as epidermal growth 
factor receptor and anaplastic lymphoma kinase inhibitors to overcome resistance to their early generation counter-
parts; and (2) deeper understanding of tumor genetics of each individual patient and consequently the application 
of biomarkers to guide personalized treatment as well as novel drug development including combination therapy. 
The increasing capacity in innovative cancer drug research and development is supported by extensive collaboration 
within China and globally, and across academia and industry, to build up expertise and infrastructure in early-phase 
clinical testing of novel drugs. With these combined efforts, new and better medicines will be available for lung can-
cer patients in China in the near future.
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Lung cancer, the most prevalent and deadly malignancy, 
accounts for a staggering 1.6 million new cases diagnosed 
every year and approximately 21% of cancer deaths to 
the global cancer burden [1]. In China, lung cancer has 
become a particularly challenging disease because of air 
pollution and smoking with an estimated 733,280 new 
cases every year and 671,625 cancer-related deaths [2–
5]. In this special issue of the Chinese Journal of Cancer 
(CJC), we have organized a series of articles reviewing the 
global collaborative effort in improving lung cancer treat-
ment in China.
Lung cancer treatment in China has shown substantial 
advancements in recent years exemplified by the inte-
gration of targeted therapies in standard of care. In the 
landmark Iressa Pan-ASia Study (IPASS) study, gefitinib 
(Iressa), a mutated epidermal growth factor receptor 
(EGFR) inhibitor, demonstrated superiority to carbopl-
atin and paclitaxel in treating patients with lung cancer 
in East Asia [6]. A follow-up study confirmed that EGFR 
mutation is the strongest predictive biomarker for pro-
gression-free survival and tumor response to first-line 
gefitinib versus carboplatin and paclitaxel [7]. Similarly, 
crizotinib (Xalkori), an anaplastic lymphoma kinase 
(ALK) inhibitor, has shown superiority compared with 
chemotherapy in lung cancer patients with ALK translo-
cation [8]. The high prevalence of activating EGFR muta-
tions (32.7%) and ALK rearrangements (6.8%) among 
lung cancer patients in China has further expanded the 
use of these targeted agents [9]. However, the enthusiasm 
in using these targeted agents also brought up new chal-
lenges in clinical practice including the debate of whether 
such agents can and should be used in patients with wild-
type targets as reviewed by Zhou et al. [10]. The review 
provides an important perspective in the context of rela-
tively scarce healthcare resources and the heterogeneous 
diagnostic approaches in China.
Despite the encouraging clinical efficacy delivered by 
targeted agents, these monotherapies benefit only small 
subsets of patients with oncogene-driven tumors and, 
further, virtually all develop resistance and succumb to 
relapsed diseases [11]. Depending on the mechanisms 
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of resistance, patients with relapsed diseases may fur-
ther benefit from (1) new generation of targeted agents 
designed to address the resistance mechanisms; and (2) 
combination therapy to target multiple pathways simul-
taneously including resistance mechanisms.
The article by Xu [12] describes the discovery and 
development of avitinib, an investigational third-genera-
tion EGFR inhibitor originally discovered in China, and 
is being developed in China and the United States (US). 
Similar to other third-generation EGFR inhibitors such as 
AZD9291 and CO1686, avitinib irreversibly inhibits the 
mutant EGFR, spares the wild-type EGFR thus avoiding 
or minimizing normal tissue toxicities, and overcomes 
T790M mutation-mediated resistance to early-gener-
ation EGFR inhibitors. The ongoing phase 1 study of 
avitinib in China in lung cancer patients with T790M 
mutation will provide the first set of clinical data of third-
generation EGFR inhibitors in Chinese patients. The 
parallel clinical development in the US as an integrated 
global development strategy will generate data in relevant 
patient population in which other third-generation EGFR 
inhibitors are being investigated. It is highly expected 
that avitinib, an innovative drug discovered in China, has 
the potential to become the first-in-class new generation 
EGFR inhibitor in China.
The successful clinical approach to effectively treat-
ing lung cancer and addressing drug-resistance relies on 
the use of biomarkers to personalize cancer treatment. 
The review article by Fang et  al. [13] from MD Ander-
son Cancer Center discusses predictive biomarkers not 
only for traditional targeted agents such as inhibitors 
of EGFR, ALK, and c-ros oncogene 1 receptor tyrosine 
kinase (ROS1) but also for immune checkpoint inhibi-
tors. The article also highlights the need for identifying 
predictive biomarkers in anticancer drug development. 
To succeed in such biomarker-based drug development 
approach, a mature network of clinical trial sites with 
sound translational medicine capability is a prerequi-
site. Yang et al. [14] analyzed early-phase clinical trials in 
lung cancer in the US and conducted a comparison with 
the trials conducted by the Chinese Thoracic Oncology 
Group (CTONG), the first and largest thoracic oncology 
corporative group in China. The high percentage of early-
phase clinical trials in the US provides a solid foundation 
for identifying, developing, and validating biomarkers to 
expedite drug development in late phases. In contrast, 
CTONG has yet to conduct a single early-phase clinical 
trial since its inception in 2007 at the time of the analy-
sis. Part of the reasons for this discrepancy between the 
US and China resides in the lack of clinical trial staff, e.g., 
physicians and nurses, with experience in early-phase 
oncology trials. To address this gap, the US Chinese Anti-
Cancer Association (USCACA), with generous support 
from Jiangsu Hengrui Medicine Co., LTD, has initiated 
the Early Phase Oncology Research Training (EFFORT) 
Program [15]. The scholarship will support training of 
young investigators from China in collaboration with US 
cancer centers and National Cancer Institute. Through 
short rotation programs, Chinese young investigators 
will gain experience in designing and conducting early-
phase oncology clinical trials and bring the best practice 
to their home institutes in China [14].
We firmly believe that the advancement in our under-
standing in genetics underlying lung cancer, the rap-
idly growing innovative drug research and development 
(R&D) capacity, the enhanced global collaboration, and 
the expanding capability in cancer drug clinical develop-
ment will lead to the next wave of breakthroughs in the 
treatment of lung cancer in a personalized fashion in 
China.
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